{"id":2437,"date":"2022-10-27T14:51:46","date_gmt":"2022-10-27T12:51:46","guid":{"rendered":"http:\/\/grupo.us.es\/healthterritory\/?p=2437"},"modified":"2022-10-28T13:04:11","modified_gmt":"2022-10-28T11:04:11","slug":"28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3","status":"publish","type":"post","link":"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/","title":{"rendered":"Un total de 1800 pacientes con enfermedades reum\u00e1ticas participaron en la primera fase de REUMAVID (Julio 2020)"},"content":{"rendered":"<p>1800 pacientes con 15 enfermedades reum\u00e1ticas distintas participaron en la primera fase de REUMAVID. Durante el inicio de la pandemia COVID-19, m\u00e1s de la mitad de los pacientes anul\u00f3 su cita con el reumat\u00f3logo. Adem\u00e1s, muchos de ellos aumentaron el consumo de h\u00e1bitos nocivos (24.6% fumaba m\u00e1s y el 18.2% consum\u00eda m\u00e1s alcohol) y disminuyeron la realizaci\u00f3n de actividades f\u00edsicas beneficiosas (45.6%). Con todo esto, se encontr\u00f3 que casi la mitad ten\u00edan un pobre bienestar (49.0%), y que los riesgos de ansiedad y depresi\u00f3n eran muy altos (57.% y 45.9% respectivamente).<\/p>\n<p>Estos datos se encuentran publicados en la revista <a href=\"https:\/\/rmdopen.bmj.com\/content\/7\/1\/e001546\"> RMD open<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>1800 pacientes con 15 enfermedades reum\u00e1ticas distintas participaron en la primera fase de REUMAVID. Durante el inicio de la pandemia COVID-19, m\u00e1s de la mitad de los pacientes anul\u00f3 su cita con el reumat\u00f3logo. Adem\u00e1s, muchos de ellos aumentaron el consumo de h\u00e1bitos nocivos (24.6% fumaba m\u00e1s y el 18.2% consum\u00eda m\u00e1s alcohol) y disminuyeron&hellip;<\/p>\n","protected":false},"author":7,"featured_media":2438,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[],"class_list":["post-2437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias","category-37","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Un total de 1800 pacientes con enfermedades reum\u00e1ticas participaron en la primera fase de REUMAVID (Julio 2020) - Health &amp; Territory Research<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un total de 1800 pacientes con enfermedades reum\u00e1ticas participaron en la primera fase de REUMAVID (Julio 2020) - Health &amp; Territory Research\" \/>\n<meta property=\"og:description\" content=\"1800 pacientes con 15 enfermedades reum\u00e1ticas distintas participaron en la primera fase de REUMAVID. Durante el inicio de la pandemia COVID-19, m\u00e1s de la mitad de los pacientes anul\u00f3 su cita con el reumat\u00f3logo. Adem\u00e1s, muchos de ellos aumentaron el consumo de h\u00e1bitos nocivos (24.6% fumaba m\u00e1s y el 18.2% consum\u00eda m\u00e1s alcohol) y disminuyeron&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Health &amp; Territory Research\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T12:51:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-28T11:04:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/grupo.us.es\/newthterritory\/wp-content\/uploads\/2022\/10\/reumatic.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"781\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jos\u00e9 Correa Fern\u00e1ndez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jos\u00e9 Correa Fern\u00e1ndez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/\",\"url\":\"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/\",\"name\":\"Un total de 1800 pacientes con enfermedades reum\u00e1ticas participaron en la primera fase de REUMAVID (Julio 2020) - Health &amp; Territory Research\",\"isPartOf\":{\"@id\":\"https:\/\/grupo.us.es\/healthterritory\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/grupo.us.es\/healthterritory\/wp-content\/uploads\/2022\/10\/reumatic.jpg\",\"datePublished\":\"2022-10-27T12:51:46+00:00\",\"dateModified\":\"2022-10-28T11:04:11+00:00\",\"author\":{\"@id\":\"https:\/\/grupo.us.es\/healthterritory\/#\/schema\/person\/6edfd257e38aaa36b2d51b61392dfb7b\"},\"breadcrumb\":{\"@id\":\"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/#primaryimage\",\"url\":\"https:\/\/grupo.us.es\/healthterritory\/wp-content\/uploads\/2022\/10\/reumatic.jpg\",\"contentUrl\":\"https:\/\/grupo.us.es\/healthterritory\/wp-content\/uploads\/2022\/10\/reumatic.jpg\",\"width\":781,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/grupo.us.es\/newthterritory\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un total de 1800 pacientes con enfermedades reum\u00e1ticas participaron en la primera fase de REUMAVID (Julio 2020)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/grupo.us.es\/healthterritory\/#website\",\"url\":\"https:\/\/grupo.us.es\/healthterritory\/\",\"name\":\"Health &amp; Territory Research\",\"description\":\"Interdisciplinary Research Group of the University of Seville\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/grupo.us.es\/healthterritory\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/grupo.us.es\/healthterritory\/#\/schema\/person\/6edfd257e38aaa36b2d51b61392dfb7b\",\"name\":\"Jos\u00e9 Correa Fern\u00e1ndez\",\"sameAs\":[\"http:\/\/grupo.us.es\/healthterritory\/\"],\"url\":\"https:\/\/grupo.us.es\/healthterritory\/author\/pepe\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un total de 1800 pacientes con enfermedades reum\u00e1ticas participaron en la primera fase de REUMAVID (Julio 2020) - Health &amp; Territory Research","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/","og_locale":"es_ES","og_type":"article","og_title":"Un total de 1800 pacientes con enfermedades reum\u00e1ticas participaron en la primera fase de REUMAVID (Julio 2020) - Health &amp; Territory Research","og_description":"1800 pacientes con 15 enfermedades reum\u00e1ticas distintas participaron en la primera fase de REUMAVID. Durante el inicio de la pandemia COVID-19, m\u00e1s de la mitad de los pacientes anul\u00f3 su cita con el reumat\u00f3logo. Adem\u00e1s, muchos de ellos aumentaron el consumo de h\u00e1bitos nocivos (24.6% fumaba m\u00e1s y el 18.2% consum\u00eda m\u00e1s alcohol) y disminuyeron&hellip;","og_url":"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/","og_site_name":"Health &amp; Territory Research","article_published_time":"2022-10-27T12:51:46+00:00","article_modified_time":"2022-10-28T11:04:11+00:00","og_image":[{"width":781,"height":533,"url":"https:\/\/grupo.us.es\/newthterritory\/wp-content\/uploads\/2022\/10\/reumatic.jpg","type":"image\/jpeg"}],"author":"Jos\u00e9 Correa Fern\u00e1ndez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Jos\u00e9 Correa Fern\u00e1ndez","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/","url":"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/","name":"Un total de 1800 pacientes con enfermedades reum\u00e1ticas participaron en la primera fase de REUMAVID (Julio 2020) - Health &amp; Territory Research","isPartOf":{"@id":"https:\/\/grupo.us.es\/healthterritory\/#website"},"primaryImageOfPage":{"@id":"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/#primaryimage"},"image":{"@id":"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/#primaryimage"},"thumbnailUrl":"https:\/\/grupo.us.es\/healthterritory\/wp-content\/uploads\/2022\/10\/reumatic.jpg","datePublished":"2022-10-27T12:51:46+00:00","dateModified":"2022-10-28T11:04:11+00:00","author":{"@id":"https:\/\/grupo.us.es\/healthterritory\/#\/schema\/person\/6edfd257e38aaa36b2d51b61392dfb7b"},"breadcrumb":{"@id":"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/#primaryimage","url":"https:\/\/grupo.us.es\/healthterritory\/wp-content\/uploads\/2022\/10\/reumatic.jpg","contentUrl":"https:\/\/grupo.us.es\/healthterritory\/wp-content\/uploads\/2022\/10\/reumatic.jpg","width":781,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/grupo.us.es\/healthterritory\/28-04-2021-el-proyecto-imas-consigue-el-premio-connecting-healthcare-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/grupo.us.es\/newthterritory\/"},{"@type":"ListItem","position":2,"name":"Un total de 1800 pacientes con enfermedades reum\u00e1ticas participaron en la primera fase de REUMAVID (Julio 2020)"}]},{"@type":"WebSite","@id":"https:\/\/grupo.us.es\/healthterritory\/#website","url":"https:\/\/grupo.us.es\/healthterritory\/","name":"Health &amp; Territory Research","description":"Interdisciplinary Research Group of the University of Seville","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/grupo.us.es\/healthterritory\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/grupo.us.es\/healthterritory\/#\/schema\/person\/6edfd257e38aaa36b2d51b61392dfb7b","name":"Jos\u00e9 Correa Fern\u00e1ndez","sameAs":["http:\/\/grupo.us.es\/healthterritory\/"],"url":"https:\/\/grupo.us.es\/healthterritory\/author\/pepe\/"}]}},"wps_subtitle":"","_links":{"self":[{"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/posts\/2437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/comments?post=2437"}],"version-history":[{"count":2,"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/posts\/2437\/revisions"}],"predecessor-version":[{"id":2444,"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/posts\/2437\/revisions\/2444"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/media\/2438"}],"wp:attachment":[{"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/media?parent=2437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/categories?post=2437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grupo.us.es\/healthterritory\/wp-json\/wp\/v2\/tags?post=2437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}